SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?

To: poodle who wrote (1226)12/21/1998 9:38:00 AM
From: Emec  Read Replies (2) | Respond to of 1510
 
"Although the treatment effect was not maintained throughout the trial in the entire
patient population, " sounds not very promising.

You misread this. It goes on to say when prednisone was removed the remainder of the patients appear to have had a greater treatment effect...



To: poodle who wrote (1226)12/21/1998 9:39:00 AM
From: Emec  Respond to of 1510
 
these results MAY support the Company's BELIEF that the TCR peptide therapeutic vaccine is a useful approach for the treatment of rheumatoid arthritis."

IMHO, IMNR has made the understatement of 1998 with the above statement


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News